On 23 January, 2008 the Public Patent Foundation announced that the USPTO rejected four patents assigned to Gilead Sciences that related to the HIV/AIDS drug tenofovir disoproxil fumarate (TDF). The Public Patent Foundation filed a third party request for re-examination, submitting prior art that had not been disclosed in the patent prosecution process. For more information on the patents, the reexaminations, and the Public Patent Foundation, see: http://www.pubpat.org/gileadhi
